Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (197,723)	$ (143,883)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	620	521
Stock-based compensation	24,133	16,812
Issuance of PIK interest debt	3,484	990
Accrued interest on revenue interest financing liability	14,079
Amortization of debt discount	2,110	3,595
Other	1,329	823
Changes in operating assets and liabilities:
Prepaid expenses and other current assets (includes changes in related party amounts of $0 and $82, respectively)	(1,860)	605
Accounts payable and accrued expenses (includes changes in related party amounts of $1,139 and $2,766, respectively)	8,679	(9,791)
Accrued clinical trial expenses	(1,402)	(18,595)
Accrued interest	377	165
Operating right-of-use assets and lease liabilities	(238)	98
Other long-term assets	(118)	203
Net cash used in operating activities	(146,530)	(148,457)
Cash flows from investing activities
Cash paid for property, plant and equipment	(1,041)	(328)
Net cash used in investing activities	(1,041)	(328)
Cash flows from financing activities
Proceeds from issuance of common stock from exercise of stock options		1,944
Repayment of long-term debt		(54,125)
Net proceeds from issuance of long-term debt		96,889
Net proceeds from revenue interest financing transaction	95,446
Net cash provided by financing activities	120,042	44,708
Net decrease in cash and cash equivalents and restricted cash	(27,529)	(104,077)
Cash and cash equivalents – beginning of period	183,419	287,496
Cash and cash equivalents – end of period	155,890	183,419
Supplemental disclosure of cash flow information
Interest paid	7,033	4,069
Supplemental disclosure of noncash investing and financing activities
Issuance of common stock warrants in connection with long-term debt		1,290
Property and equipment purchases included in accounts payable and accrued expenses	138	2
Final interest payment fee		7,500
Settlement of ESPP liability in common stock	909	819
Settlement of 401(k) liability in common stock	1,116	$ 903
Operating lease liabilities arising from obtaining right-of-use assets	554
At-the-Market Offering Program
Cash flows from financing activities
Net proceeds from issuance of common stock	$ 24,596